Lifeward (ReWalk Robotics)
33 Locke Drive
2nd Floor
Marlborough
Massachusetts
01752
United States
Tel: 1-508-251-1154
Website: http://rewalk.com/
125 articles about Lifeward (ReWalk Robotics)
-
ReWalk Robotics to Report Second Quarter 2022 Financial Results on August 9, 2022
8/3/2022
ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that the Company will release its second quarter 2022 financial results on Tuesday, August 9, 2022, at 8:30 AM Eastern time.
-
ReWalk Robotics Announces Results of 2022 Annual Meeting
8/2/2022
ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced the results of the Company's 2022 Annual Meeting of Shareholders (the “Annual Meeting”) based on the final tabulation of votes certified by an independent Inspector of Elections.
-
ReWalk Receives Court Approval for Share Repurchase Program
7/21/2022
ReWalk Robotics Ltd. (Nasdaq: RWLK) (the “Company” or “ReWalk”), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced that it has received Israeli court approval to repurchase up to $8 million of its Ordinary Shares, par value NIS 0.25 per share.
-
ReWalk Robotics Reports First Quarter 2022 Financial Results
5/13/2022
ReWalk Robotics Ltd. announced its financial results for the three months ended March 31, 2022.
-
ReWalk Robotics Announces the Appointment of Joseph E. Turk, Jr. to their Board of Directors
4/20/2022
ReWalk Robotics. Ltd. announced that the Board has approved the appointment of Joseph Turk, Jr. to the Board of Directors.
-
ReWalk Robotics Reports Fourth Quarter and Year End 2021 Financial Results
2/24/2022
ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced its financial results for the three and twelve-months ended December 31, 2021.
-
ReWalk Robotics to Report Fourth Quarter 2021 Financial Results on February 24, 2022
2/21/2022
ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that the Company will release its fourth quarter 2021 financial results on Thursday, February 24, 2022, before the U.S. financial markets open.
-
ReWalk Robotics Reports Third Quarter 2021 Financial Results
11/10/2021
ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced its financial results for the three and nine months ended September 30, 2021.
-
ReWalk Robotics to Hold its Third Quarter 2021 Earnings Call on November 11, 2021
11/5/2021
ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that management will hold its third quarter 2021 earnings call Thursday, November 11, 2021, at 8:30 AM Eastern time.
-
FDA Awards Breakthrough Device Designation to the ReWalk ReBoot Soft Exo-Suit
11/4/2021
ReWalk Robotics, Ltd. today announced its ReBoot device has been granted designation as a Breakthrough Device by the Food and Drug Administration (FDA).
-
ReWalk Robotics Announces $32.5 Million Registered Direct Offering Priced At Premium to Market
9/27/2021
ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that it has entered into definitive agreements with several institutional investors providing for the issuance of 16,013,518 of the Company’s ordinary shares (or ordinary share equivalents in lieu thereof), at an effective purchase price of $2.035, in a registered direct offering priced at-the-market under Nasdaq Rules.
-
ReWalk Robotics Reports Second Quarter 2021 Financial Results
8/9/2021
ReWalk Robotics Ltd. announced its financial results for the three and six months ended June 30, 2021.
-
ReWalk Robotics Appoints Senior Biotech Executive, Jeannine Lynch, as Vice President of Strategy and Market AccessMs. Lynch will lead ongoing building and implementation of ReWalk’s market access and reimbursement programs
8/2/2021
ReWalk Robotics Ltd. today announced Jeannine Lynch will join the Company on August 31, 2021, as Vice President of Strategy and Market Access.
-
ReWalk Robotics Reports First Quarter 2021 Financial Results
5/11/2021
ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced its financial results for the three months ended March 31, 2021. Highlights of and subsequent to the first quarter of 2021 include: The Company’s total revenue in the first quarter of 2021
-
ReWalk Robotics to Present at the H.C. WAINWRIGHT Global Life Sciences Virtual Conference
3/4/2021
ReWalk Robotics Ltd. announced that Larry Jasinski, Chief Executive Officer and Ori Gon, Chief Financial Officer will present at H.C.WAINWRIGHT global life science conference held on March 9 – 10, 2021.
-
National Institute for Health and Care Excellence (NICE) Publishes Briefing on ReStore Soft Exo-Suit in the UK
3/3/2021
Experts outline potential for improved stroke patient outcomes, cost effectiveness through use of the ReStore device in the rehabilitation setting
-
ReWalk Enters Contract with BKK Mobil Oil health insurance fund for the supply of ReWalk exoskeleton to eligible persons with spinal cord injury in Germany
3/2/2021
ReWalk Robotics, Ltd., a leading manufacturer of robotic medical devices for people with lower extremity disabilities, announced it has entered into a contract with BKK Mobil Oil Insurance to provide ReWalk Personal Exoskeleton devices to its eligible beneficiaries with spinal cord injury.
-
ReWalk Robotics Announces Closing of $40.0 Million Private Placement Priced At-the-Market
2/26/2021
ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced the closing of its previously announced private placement of 10,921,502 ordinary shares and warrants to purchase up to 5,460,751 ordinary shares, at a purchase price of $3.6625 per share and associated warrant, that was priced “at-the-market” under Nasdaq rules and resulted in gross proceeds of approximately $40.0 million
-
ReWalk Robotics Announces $40.0 Million Private Placement Priced At-the-Market
2/19/2021
ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that it has entered into securities purchase agreements with certain institutional and other accredited investors to raise $40.0 million through the issuance of 10,921,502 ordinary shares and warrants to purchase up to 5,460,751 ordinary shares,
-
ReWalk Robotics Reports Fourth Quarter and Year End 2020 Financial Results
2/18/2021
Continued CMS progress made with issuance of HCPCS Level II Code for ReWalk Exoskeleton enabling an upcoming application for coverage